Evidence map›Paper›PMID 29253862›Full record

ArticlePloS one2017

The interruption of Onchocerca volvulus and Wuchereria bancrofti transmission by integrated chemotherapy in the Obongi focus, North Western Uganda.

Lakwo Thomson Luroni, Matwale Gabriel, Edridah Tukahebwa, Ambrose Winston Onapa, Benjamin Tinkitina, Ephraim Tukesiga, Michael Nyaraga, Anna Mary Auma, Peace Habomugisha, Edson Byamukama and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Lymphatic Filariasis Elimination Status:Tropical medicine and infectious disease · 2023
    Article
  5. Article
  6. Operational Performance of theThe American journal of tropical medicine and hygiene · 2018
    Article
  7. Onchodermatitis: Where Are We Now?Tropical medicine and infectious disease · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Lakwo Thomson LuroniVector Control Division, Ministry of Health, Kampala, Uganda.ORCID http://orcid.org/0000-0002-7081-5323
Matwale GabrielVector Control Division, Ministry of Health, Kampala, Uganda.
Edridah TukahebwaVector Control Division, Ministry of Health, Kampala, Uganda.
Ambrose Winston OnapaEnvision/RTI- Neglected Tropical Diseases Control Programme, Kampala, Uganda.
Benjamin TinkitinaVector Control Division, Ministry of Health, Kampala, Uganda.
Ephraim TukesigaKabarole District Local Government, Fort Portal, Uganda.
Michael NyaragaMoyo District Local Government, Medical Department, Moyo, Uganda.
Anna Mary AumaVector Control Division, Ministry of Health, Kampala, Uganda.
Peace HabomugishaThe Carter Center, Uganda office, Kampala, Uganda.
Edson ByamukamaThe Carter Center, Uganda office, Kampala, Uganda.
David OguttuVector Control Division, Ministry of Health, Kampala, Uganda.
Moses KatabarwaThe Carter Center, Atlanta, United States of America.
Thomas Raymond UnnaschUniversity of South Florida, Global Health Infectious Disease Research, College of Public Health, Tampa, FL, United States of America.
Ministry of Health · UGCarter Center · USUniversity of South Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

interventionFew studies have documented the interruption of onchocerciasis and Lymphatic Filariasis (LF) by integrated chemotherapy in Uganda. The study describes the interruption of transmission of the two diseases co-endemic in Obongi focus, north western Uganda. Base line data for Onchocerciasis and LF were collected in 1994 and 2006, respectively. Annual mass drug administration for onchocerciasis (Ivermectin) and Lymphatic Filariasis (Ivermectin + albendazole) was conducted for 20 and 6 years, respectively. Thereafter, assessments by skin snip, larval searches in rivers and human landing catches were performed. Children <10 years were screened for IgG4 antibodies using Ov16 ELISA technique in 2013. LF Pre-TAS and TAS1 were conducted in sentinel sites. ITN coverage and utilization for the implementation unit was also reported. INTERVENTION COVERAGE: Onchocerciasis treatment coverage was <80% but improved with the introduction of CDTI in 1999. While for LF, effective coverage of >65% was achieved in the six treatment rounds. Household ownership of ITN's and utilization was 96% and 72.4%., respectively. IMPACT: Parasitological examinations conducted for onchocerciasis among 807 adults and children, revealed a reduction in mf prevalence from 58% in 1994 to 0% in 2012. Entomological monitoring conducted at the two sites had no single Simulium damnosum fly caught. Serological analysis using Ov16 ELISA for onchocerciasis revealed that out of the 3,308 children <10 years old screened in 2013, only 3/3308 (0.091%) positive cases were detected. All Ov16 positive children were negative when tested for patent infection by skin snip PCR. A reduction in LF microfilaria prevalence from 2.5% (n = 13/522) in 2006 to 0.0% (n = 602) in 2014 was observed. LF TAS1 conducted in 2015 among 1,532 children 6-7 years, all were negative for antigens of W. bancrofti.

conclusionThe results concluded that interruption of onchocerciasis and LF has been achieved.

Indexed as

Onchocerca volvulusWuchereria bancroftiAdolescentAlbendazoleAnimalsAntiparasitic AgentsChildChild, PreschoolElephantiasis, FilarialEnzyme-Linked Immunosorbent AssayFemaleHumansImmunoglobulin GIvermectinMaleOnchocerciasisAlbendazoleAntiparasitic AgentsImmunoglobulin GIvermectin

Identifiers

PMID29253862
PMCPMC5734780
OpenAlexW2775981162

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.